Navigation Links
Drug therapy for allergy moves forward
Date:5/12/2014

Researchers have identified several target molecules which are suitable for the development of new allergy drugs. The Journal of Allergy and Clinical Immunology, the most prestigious journal in the field of allergology, has recently published an extensive review article on the prospects of drug therapy for allergy. Completed in a large-scale EU project, the lead author of the review article is Professor Ilkka Harvima of the University of Eastern Finland and Kuopio University Hospital.

Immediate allergic reactions and allergic diseases such as allergic rhinitis, asthma and urticaria are extremely widespread in the population. Traditionally, drug therapy for allergy is based on the use of non-sedative antihistamines, i.e. blocking of the histamine H1 receptors, but sometimes additional help is obtained from blockers of the cysteinyl leukotriene receptor-1.

Antihistamines seek to prevent allergic symptoms caused by histamine released by mast cells. Mast cells, also known as "allergy cells", are cells of the immune system which become activated by environmental allergens.

"However, even high doses of H1 antihistamine drugs aren't enough to alleviate the symptoms of some patients. This is understandable, as when the mast cell becomes activated, several other strong mediators besides histamine get released, too. Histamine can also affect other receptors of the cell surface than the H1 receptor," Professor Harvima explains.

Over the past years, researchers have identified several mast cell molecules which can be targets of new drugs. Several of these have already proceeded to clinical trials. These targets include, for example, serine proteinases tryptase, chymase, cathepsin G, which are enzymes that break down proteins, as well as 5-lipoxygenase-activating protein FLAP, 15-lipoxygenase-1, prostaglandin-D2, and proinflammatory cytokines such as TNF-alpha, IL-4, IL-6 and IL-17. New drugs targeting the histamine H4 receptor are
'/>"/>

Contact: Ilkka Harvima
ilkka.harvima@kuh.fi
358-447-172-875
University of Eastern Finland
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Two-lock box delivers cancer therapy
2. WHI reports $37.1B economic return on combined hormone therapy clinical trial
3. Study finds family-based exposure therapy effective treatment for young children with OCD
4. No credible evidence to support cardiac risk of testosterone therapy
5. Outcomes of steroid therapy following surgery for infants with bile duct disorder
6. New combination therapy developed for multiple myeloma
7. New model can predict therapy outcomes in prostate cancer with bone metastasis
8. Stress research in therapy dogs reveals animals needs
9. Receiving chemotherapy after a breast cancer diagnosis may affect a patients employment
10. ASTRO issues guideline on the role of postoperative radiation therapy for endometrial cancer
11. Massage therapy improves circulation, eases muscle soreness
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... Terminsurancevirginia.com has released a new blog post ... insurance for obese clients. , Obese clients can ... It is unlikely for applicants to be denied coverage ... insurance costs. , Having life insurance is important ... insurance is available as temporary or permanent coverage and ...
(Date:9/16/2014)... Insuranceservicecompany.com has released a new blog ... investment tool. , Whole life insurance can provide financial ... used as an investment tool. Clients can save money for ... , A whole life insurance plan features a savings ... order for this policy to be profitable, clients should purchase ...
(Date:9/16/2014)... adage that warns against passing judgment based on ... species, apparently don,t share such human wisdom when ... University Polytechnic School of Engineering found that female ... fin color: yellow. The preference for yellow was ... , The reason may lie in the engineering-based, ...
(Date:9/16/2014)... According to a report by iData Research ( ... market research, the market for enteral feeding devices is ... U.S . and Europe combined. The market ... tubes, DPEJ tubes, PEG/J tubes. The enteral feeding replacement ... non-balloon tubes, nasogastric and nasojejunal tubes, enteral feeding pumps ...
(Date:9/16/2014)... 2014 Care Logistics® announced the ... of the Hospital Operating System™ that allows hospitals ... with staff capacity. For the first time, bed ... nursing and other staff capacity. , “The Demand ... anticipated admissions, discharges and transfers, real staff capacity ...
Breaking Medicine News(10 mins):Health News:Obese Clients Can Find Affordable No Exam Term Life Insurance at Terminsurancevirginia.com! 2Health News:Whole Life Insurance Can Be A Good Investment Tool for Retirement! 2Health News:Judging a fish by its color: for female bluefin killifish, love is a yellow mate 2Health News:Judging a fish by its color: for female bluefin killifish, love is a yellow mate 3Health News:Over 17 Million Enteral Feeding Device Placement Procedures is Expected to be Performed in the U.S. and Europe in 2020: Market Led by Covidien, Kimberly-Clark and Abbott 2Health News:Over 17 Million Enteral Feeding Device Placement Procedures is Expected to be Performed in the U.S. and Europe in 2020: Market Led by Covidien, Kimberly-Clark and Abbott 3Health News:Care Logistics Launches Demand Logistics as Part of the Hospital Operating System 2
... ) launches the GlaceComplete product suite which seamlessly integrates EMR ... billing process. The product has been designed to reduce the ... for the average office based medical practice. , ... ...
... piezoelectric transducers in industrial applications, and to facilitate transducer evaluation in ... ... 26, 2009 -- Piezoelectric elements have a myriad of uses. They ... in a structure. They can be used to acoustically cancel noise, ...
... that is responsible for maintaining the health of the light-sensing ... retina for the first time. , The ability to see ... of many diseases of the eye long before a patient ... Investigative Ophthalmology and Visual Science ., "Our goal is to ...
... Feb. 25 PharmaNet Development Group, Inc. (the "Company") ... clinical development services, today reported preliminary net income for ... million, or $0.08 per diluted share, compared to net ... per diluted share, in the fourth quarter 2007. All ...
... for February 26, 2009 at 10:00 a.m. EST , EAST ... SVNT ) today reported financial results for the three months and ... 2008, the Company had a net loss of $24.2 million, or ... the year ended December 31, 2008, the Company had a net ...
... with record bookings and continued positive cash flow ... AMCS ), a leader in radiology ... reported unaudited financial results for the fourth quarter ... http://www.newscom.com/cgi-bin/prnh/20060202/AMICASLOGO ) Q4 Financial Highlights Revenue ...
Cached Medicine News:Health News:Glenwood Systems, LLC Improves Medical Billing Process with GlaceComplete 2Health News:Glenwood Systems, LLC Improves Medical Billing Process with GlaceComplete 3Health News:Amped Up Piezos Are On The Move - Driving Piezos with an Affordable High Voltage Piezo Amplifier QPA200 2Health News:Amped Up Piezos Are On The Move - Driving Piezos with an Affordable High Voltage Piezo Amplifier QPA200 3Health News:'Dark cells' of living retina imaged for the first time 2Health News:'Dark cells' of living retina imaged for the first time 3Health News:PharmaNet Development Group Reports Fourth Quarter and Full Year 2008 Preliminary Financial Results 2Health News:PharmaNet Development Group Reports Fourth Quarter and Full Year 2008 Preliminary Financial Results 3Health News:PharmaNet Development Group Reports Fourth Quarter and Full Year 2008 Preliminary Financial Results 4Health News:PharmaNet Development Group Reports Fourth Quarter and Full Year 2008 Preliminary Financial Results 5Health News:PharmaNet Development Group Reports Fourth Quarter and Full Year 2008 Preliminary Financial Results 6Health News:PharmaNet Development Group Reports Fourth Quarter and Full Year 2008 Preliminary Financial Results 7Health News:PharmaNet Development Group Reports Fourth Quarter and Full Year 2008 Preliminary Financial Results 8Health News:PharmaNet Development Group Reports Fourth Quarter and Full Year 2008 Preliminary Financial Results 9Health News:PharmaNet Development Group Reports Fourth Quarter and Full Year 2008 Preliminary Financial Results 10Health News:PharmaNet Development Group Reports Fourth Quarter and Full Year 2008 Preliminary Financial Results 11Health News:PharmaNet Development Group Reports Fourth Quarter and Full Year 2008 Preliminary Financial Results 12Health News:PharmaNet Development Group Reports Fourth Quarter and Full Year 2008 Preliminary Financial Results 13Health News:PharmaNet Development Group Reports Fourth Quarter and Full Year 2008 Preliminary Financial Results 14Health News:PharmaNet Development Group Reports Fourth Quarter and Full Year 2008 Preliminary Financial Results 15Health News:PharmaNet Development Group Reports Fourth Quarter and Full Year 2008 Preliminary Financial Results 16Health News:PharmaNet Development Group Reports Fourth Quarter and Full Year 2008 Preliminary Financial Results 17Health News:Savient Pharmaceuticals Reports Fourth Quarter and Year-End 2008 Financial Results 2Health News:Savient Pharmaceuticals Reports Fourth Quarter and Year-End 2008 Financial Results 3Health News:Savient Pharmaceuticals Reports Fourth Quarter and Year-End 2008 Financial Results 4Health News:Savient Pharmaceuticals Reports Fourth Quarter and Year-End 2008 Financial Results 5Health News:Savient Pharmaceuticals Reports Fourth Quarter and Year-End 2008 Financial Results 6Health News:Savient Pharmaceuticals Reports Fourth Quarter and Year-End 2008 Financial Results 7Health News:Savient Pharmaceuticals Reports Fourth Quarter and Year-End 2008 Financial Results 8Health News:Savient Pharmaceuticals Reports Fourth Quarter and Year-End 2008 Financial Results 9Health News:AMICAS Reports Financial Results for the Fourth Fiscal Quarter and Year Ended December 31, 2008 2Health News:AMICAS Reports Financial Results for the Fourth Fiscal Quarter and Year Ended December 31, 2008 3Health News:AMICAS Reports Financial Results for the Fourth Fiscal Quarter and Year Ended December 31, 2008 4Health News:AMICAS Reports Financial Results for the Fourth Fiscal Quarter and Year Ended December 31, 2008 5Health News:AMICAS Reports Financial Results for the Fourth Fiscal Quarter and Year Ended December 31, 2008 6
(Date:9/16/2014)... , Sept. 16, 2014 Henry ... world,s largest provider of health care products and ... practitioners, announced today that Stanley M. Bergman, Henry Schein,s Chairman ... participate in a healthcare services panel at the ... Mr. Bergman will be Dr. Stohler, Dean of ...
(Date:9/15/2014)... PARIS and NEW YORK ... company Pharnext SAS and the Hereditary Neuropathy Foundation (HNF) ... increase the awareness around Charcot-Marie-Tooth (CMT) disease and support ... community. Pharnext will provide financial support ... design and development of a specific section in the ...
(Date:9/15/2014)... WALTHAM, Mass. , Sept. 15, 2014  Alere Inc. ... a global leader in infectious disease, toxicology, cardiology and ... of former executives, led by former CEO Ron ... and Exchange Commission and subsequently sent a letter to ... requesting one month of due diligence in an effort ...
Breaking Medicine Technology:Henry Schein To Present At The Leerink Partners Services Roundtable 2Pharnext and the Hereditary Neuropathy Foundation Collaborate to Increase Awareness of Charcot-Marie-Tooth Disease 2Pharnext and the Hereditary Neuropathy Foundation Collaborate to Increase Awareness of Charcot-Marie-Tooth Disease 3Pharnext and the Hereditary Neuropathy Foundation Collaborate to Increase Awareness of Charcot-Marie-Tooth Disease 4Alere Responds To Letter From Former Executives 2
... NEWTON, Mass., Nov. 3, 2010 Karyopharm Therapeutics Inc., a leader ... $20M Series A financing. The nuclear transport machinery plays an integral ... spectrum of human and animal disease. Karyopharm is focused on the ... i nhibitors of n uclear ...
... that a new market research report is available in its ... http://www.reportlinker.com/p0324749/Quality-for-Biologics.html Quality for Biologics – ... change control, product variation, characterisation, and regulatory concerns ... than sales of small molecule drugs, which grew by not ...
Cached Medicine Technology:Karyopharm Therapeutics Inc. Closes $20 Million Series A Financing to Advance Pipeline of Novel Nuclear Transport Modulators for Cancer, Inflammation and Other Disorders 2Karyopharm Therapeutics Inc. Closes $20 Million Series A Financing to Advance Pipeline of Novel Nuclear Transport Modulators for Cancer, Inflammation and Other Disorders 3Reportlinker Adds Quality for Biologics 2Reportlinker Adds Quality for Biologics 3Reportlinker Adds Quality for Biologics 4Reportlinker Adds Quality for Biologics 5Reportlinker Adds Quality for Biologics 6
... This new kit uses proteins produced with ... Latin America, and which are capable of detecting ... this area. They are proteins with amino acid ... antigen) antigen. During the acute phase of the ...
The Cellabs T. cruzi IgG CELISA is a direct ELISA kit designed to detect antibodies produced during T. cruzi infections (Chagas disease)....
... The Cypress quick test is a ... of antibodies to Trypanosoma cruzi. It ... or plasma. The method employs a unique ... which is conjugated on dye particles, and ...
... SPL defibrillator lead features a ... the flexibility and maneuverability of ... the physician who prefers a ... the SPL lead also promotes ...
Medicine Products: